Skip to main content
. Author manuscript; available in PMC: 2019 Oct 7.
Published in final edited form as: HPB (Oxford). 2018 Jan 12;20(7):597–604. doi: 10.1016/j.hpb.2017.12.010

Fig. 2.

Fig. 2

A representative PDAC with CEACAM 1/5 staining that is strong and diffuse in the tumor epithelial cells (A), whereas tenascin C staining that is strong and diffuse in the stroma (B). A representative IPMN with CEACAM 1/5 staining that is strong and diffuse in the tumor epithelial cells (C), whereas tenascin C staining that is moderate and focal in the stroma (D).